Core Viewpoint - The stock of Meihao Medical (301363) has experienced a decline, with significant net outflows from major and retail investors, while the company shows mixed financial performance indicators in the medical device industry [1][2][3]. Financial Performance - As of January 30, 2026, Meihao Medical's stock closed at 31.06 yuan, down 1.52%, with a trading volume of 100,200 hands and a transaction amount of 311 million yuan [1]. - In the last five days, the stock has seen fluctuations in net capital flow, with a net outflow of 16.94 million yuan from major funds and a net inflow of 38.80 million yuan from retail investors on January 30 [2]. - For the first three quarters of 2025, the company reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders decreased by 19.25% to 208 million yuan [3]. Industry Comparison - Meihao Medical's total market value is 17.669 billion yuan, which is higher than the industry average of 11.102 billion yuan, ranking 16th out of 127 companies in the medical device sector [3]. - The company's price-to-earnings ratio (P/E) stands at 63.65, significantly lower than the industry average of 104.17, ranking 62nd [3]. - The gross profit margin of Meihao Medical is 39.34%, which is below the industry average of 50.94%, ranking 89th [3]. Investment Sentiment - In the last 90 days, seven institutions have rated Meihao Medical with a "buy" recommendation, with an average target price of 24.57 yuan [4].

Core Viewpoint - The company, Shanwaishan, announced an expected net profit attributable to shareholders for the year 2025, projecting between 140.35 million to 159.49 million yuan, indicating a significant increase compared to the previous year [1] Financial Performance - The projected net profit increase is estimated to be between 69.47 million to 88.61 million yuan, representing a year-on-year growth of 98% to 125% [1]

证券日报网讯 1月30日，新华医疗在互动平台回答投资者提问时表示，公司历史上已累计承担/参与20 余项国家级科技项目，其中在"十二五""十三五""十四五"期间连续申报并获批国家重点研发计划，技术 与经验积淀深厚。"十五五"期间，公司将继续积极申报承担国家重点研发计划，聚焦医疗器械与制药装 备两大主业，围绕高端放疗影像、智慧感控、微创器械、高端制剂装备等方向，联合高校、医院及科研 院所，攻克"卡脖子"技术、推进国产化替代与前沿技术产业。 （编辑 姚尧） ...

Core Viewpoint - Bluefan Medical has announced an earnings forecast indicating a projected loss per share of 0.65 to 0.85 yuan for the year 2025 [1] Group 1: Reasons for Performance Fluctuation - The company's health protection division is experiencing order fluctuations due to international trade conditions, leading to pressure on sales prices and an overall significant loss for the year despite a recovery in gross margin in Q4 2025 [2] - The health protection division is undergoing a special tax adjustment related to cross-border transactions from 2020 to 2022, resulting in tax payments and interest charges that negatively impact net profit [2] - The cardiovascular division's investment in Suzhou Tongxin Medical Technology Co., Ltd. has resulted in a fair value loss of approximately 120 million yuan due to valuation changes, although this does not involve cash outflow [2] Group 2: Performance of Cardiovascular Division - Excluding the impact of Suzhou Tongxin, the cardiovascular division has shown continuous improvement, achieving a sales revenue of approximately 1.4 billion yuan in 2025, representing over a 24% increase from the previous year [3] - The sales and management expense ratios have further decreased, contributing positively to the division's profitability [3] Group 3: Financial Impacts and Other Notes - The company is expected to incur financial expenses of 100 million yuan in 2025 due to a strategic investment in its subsidiary, which will be recognized as a financial liability [3] - The company has reported a fair value gain of approximately 13 million yuan from investments in peripheral and neuro-interventional fields, contributing to overall profit [3] - The earnings forecast is based on preliminary estimates, with final financial data to be disclosed in the official annual report [3]

Investment Rating - The report does not explicitly state an investment rating for the company [1]. Core Insights - The company, Aide Technology, is a leading player in the orthopedic consumables sector, focusing on the full chain of orthopedic medical devices, including spinal, trauma, and sports medicine products, and is positioned to benefit from both aging population trends and domestic substitution opportunities [1][10]. - The company is expected to achieve a revenue of 307.48 million yuan and a net profit of 76.37 million yuan in 2025, representing year-on-year growth of 11.87% and 13.76% respectively [1]. - The orthopedic implant medical device market in China is projected to grow from 19.3 billion yuan in 2016 to 24.6 billion yuan in 2024, with a compound annual growth rate (CAGR) of 3.08% [2][9]. Company Overview - Aide Technology specializes in the research, production, and sales of orthopedic consumables, with a product range that includes spinal, trauma, sports medicine, and wound healing products [1][10]. - The company has been recognized as a national high-tech enterprise and has received various accolades, including being named a "Suzhou Brand Product" for its vertebroplasty system and external fixation bracket [1][11]. - As of November 24, 2025, the company holds 110 patents, including 45 invention patents, and has established a strong technical foundation in several core technologies [11]. Financial Performance - For the first three quarters of 2025, the company reported revenues of 222.69 million yuan and a net profit of 59.55 million yuan [1]. - The company’s gross profit margins for 2022 to the first half of 2025 were 62.45%, 57.80%, 58.05%, and 58.89% respectively [7][9]. - The company’s revenue structure is heavily reliant on manufacturing products, which accounted for 96.29% of total revenue in the first half of 2025 [41]. Industry Analysis - The orthopedic industry is experiencing a trend of price reductions due to centralized procurement policies, but the impact is expected to moderate, allowing for potential growth in non-procurement products and overseas markets [2]. - The market for vertebroplasty consumables in China grew from 800 million yuan in 2016 to 2.171 billion yuan in 2022, although it faced a decline in 2023 due to procurement policies [2][9]. - The aging population in China is expected to drive demand for orthopedic products, as the proportion of individuals aged 65 and older is steadily increasing [9].

Group 1 - The company, YHLO (688575.SH), currently does not have any products related to Nipah virus testing [1] - YHLO specializes in respiratory infection immunity, particularly in Mycoplasma pneumoniae and EB virus, which are traditional projects for the company [1] - YHLO is the first domestic biotechnology company to apply chemiluminescence technology to serological testing for Mycoplasma pneumoniae and is one of the few domestic IVD suppliers capable of providing simultaneous IgG and IgM subtype testing for Mycoplasma pneumoniae and Chlamydia [1]

100 ହ 90 80 70 60 55.0 50 48 0 4 70 45.81 40 3 3868 30 20 18.6 10 3, 2 0 2027-12-37 | 2020-12-37 1 2021-06-30 1 202-06-30 ' 2022-12-37 V +-06-30 1 3-12-37 " 3-06-30 1 2n~ ） 制图数据来自恒生聚源数据库 市净率(LF)历史分位(%) 中证智能财讯迪瑞医疗（300396）1月30日晚间披露2025年度业绩预告，预计2025年归母净利润亏损1.8亿元至3.5亿元，上年同期盈利1.42亿元；扣非净利润 亏损1.85亿元至3.6亿元，上年同期盈利1.34亿元。以最新收盘价计算，市净率（LF）约1.91倍，市销率（TTM）约7.1倍。 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 近年来市盈率变化情况（倍） 120 超 90 60 30 32d09 == 26:85 -- 27x26 23x29 20 47:44 0 -30 2020-12-37 2021-12-37 2021-06-30 ' 022-06-30 3-06-30 2 ...

（编辑 楚丽君） 证券日报网讯 1月30日，祥生医疗在互动平台回答投资者提问时表示，公司已布局超声人工智能技术多 年，推出的SonoAI软件在乳腺、肝脏、心血管、颈动脉、甲状腺、小器官和妇产科等方面均取得实质 性进展，核心技术已广泛搭载于高端推车彩超和便携新产品线。目前，公司暂不涉及脑机接口相关技术 研究。 ...

证券日报网讯 1月30日，赛诺医疗在互动平台回答投资者提问时表示，公司近年在欧洲陆续开展了冠脉 药物洗脱支架相关的系列临床研究，在产品品质方面树立了良好的口碑。在商业化方面，公司主要通过 与欧盟境内经销商合作的方式开展出口业务，业务收入在公司整体营业收入中占比尚不是很高。随着未 来更多产品获得CE认证，以及业务渠道的加强，公司有望不断提高该区域的业务收入。 （编辑 楚丽君） ...

天益医疗公告，预计2025年度净利润亏损1800万元-1100万元。本年公司联营企业宁波天辉益企业管理 有限责任公司及其新加坡全资子公司TYHC International PTE. LTD已完成对NKS持有的CRRT业务的交 割工作，2025年为交割后首年，受业务、供应链、人员及组织架构、信息系统调整等因素叠加影响，导 致其当期经营业绩承压，公司按权益法确认相关投资损失。 ...